Current Report Filing (8-k)
04 3월 2023 - 7:30AM
Edgar (US Regulatory)
0001718500
false
0001718500
2023-02-28
2023-02-28
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): February 28, 2023
REVIV3 PROCARE COMPANY
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
000-56351 |
|
47-4125218 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
|
|
|
|
|
901 Fremont Avenue, Units 158 and 168, Alhambra, California |
|
91803 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (888) 638-8882
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
Trading
Symbol(s) |
Name
of each exchange on which registered |
None |
N/A |
N/A |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item
1.01 | Entry
into a Material Definitive Agreement. |
On
February 23, 2023, Reviv3 Procare Company (the “Company”), a Delaware corporation, issued in private placements to accredited
investors an aggregate of 1,947,175 shares of its common stock, par value $0.0001 per share. The securities were issued at a purchase
price of $0.23 per share for aggregate gross proceeds to the Company of $447,850.25.
A
Form of the Securities Purchase Agreement used in the placement is filed as Exhibit 10.1 of this Form 8-K and incorporated herein by
reference. The foregoing is only a brief description of the material terms of the Securities Purchase Agreements, and does not purport
to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entirety by reference to
such exhibit.
The
Company relied on the exemption provided by Rule 506(b) of Regulation D promulgated under Section 4(a)(2) the Securities Act of 1933,
as amended (the “Act”), in connection with the foregoing transactions. Reliance on Section 4(a)(2) and Rule 506(b) of Regulation
D was based on the fact that each investor provided the Company with written representations regarding the investor's investment intent
and status as an accredited investor and neither the Company nor anyone acting on the Company’s behalf engaged in any general advertising
or general solicitation.
After
giving effect to the foregoing transactions, the number of shares of common stock outstanding as of February 28, 2023 was 117,076,949.
| Item
3.02 | Unregistered
Sales of Equity Securities. |
To
the extent required by Item 3.02 of Form 8-K, the information contained in Item 1.01 of this Current Report on Form 8-K is incorporated
herein by reference.
| Item
9.01 | Financial
Statements and Exhibits. |
(d) Exhibits.
*
Filed Herewith
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
REVIV3
PROCARE COMPANY |
Date:
March 3, 2023 |
|
|
By: |
/s/ Jeff
Toghraie |
|
Name: |
Jeff
Toghraie |
|
Title: |
Chairman
& Chief Executive Officer |
|
|
|
Reviv3 Procare (QB) (USOTC:RVIV)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Reviv3 Procare (QB) (USOTC:RVIV)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Reviv3 Procare Company (QB) (OTC 시장)의 실시간 뉴스: 최근 기사 0
More Reviv3 Procare Co News Articles